Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. (Q46945541)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Alessio Nencioni

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Anna Garuti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Karin Schwarzenberg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Gabriella Cirmena

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Giovanna Dal Bello

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Ilaria Rocco

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Eleonora Barbieri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Peter Brossart

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Franco Patrone

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

681-689

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

The proteasome: a suitable antineoplastic target

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

The development of proteasome inhibitors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Phase I study of bortezomib in refractory or relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

A proteasome inhibitor effectively prevents mouse heart allograft rejection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Proteasome is required for class I-restricted presentation by Fcgamma receptor-mediated endocytosis in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

The inhibitory role of lactacystin and beta-lactacystin on T-cell activation and proliferation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Immunobiology of dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Activation of dendritic cells: translating innate into adaptive immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Proteasome inhibitors: from research tools to drug candidates

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

The biochemistry of apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Induction of G1 arrest and apoptosis in human jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1, and Bax proteins

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Cell death: critical control points

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Structure of Bax: coregulation of dimer formation and intracellular localization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Dendritic cells in autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Dendritic cells: emerging pharmacological targets of immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Reconstructing immunity after allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535298

7 January 2021

Identifiers

DOI

10.1002/EJI.200535298

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16479541%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference